Multifunctional Hydrogel Integrated Hemangioma Stem Cell-Derived Nanovesicle-Loaded Metal-Polyphenol Network Promotes...

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Wound Healing

Background:

• Diabetes-associated skin defects pose a significant health challenge, with flap grafts often failing due to poor vascularization and infection.
• The diabetic microenvironment further compromises wound healing, necessitating advanced therapeutic strategies.

Purpose of the Study:

• To develop a novel hybrid photo-crosslinkable hydrogel (HPC) loaded with hemangioma stem cell-derived nanovesicles (HemVs) and a dual-metal-polyphenol network (dMPN) for treating diabetic skin defects.
• To evaluate the therapeutic potential of the HemV@dMPN/HPC platform in promoting angiogenesis, mitigating inflammation, and combating infection.

Main Methods:

• Fabrication of a hybrid photo-crosslinkable hydrogel (HPC) incorporating a dual-metal-polyphenol network (dMPN) loaded with hemangioma stem cell-derived nanovesicles (HemVs).
• Characterization of the HemV@dMPN/HPC platform for sustained release of copper (Cu ²⁺) and magnesium (Mg ²⁺) ions and assessment of its antibacterial properties.
• In vitro and in vivo evaluation of the platform's efficacy in promoting angiogenesis, cell proliferation, and wound closure in diabetic models.

Main Results:

• The HemV@dMPN/HPC platform demonstrated sustained release of Cu ²⁺ and Mg ²⁺ ions, promoting angiogenesis and reducing inflammation.
• HemVs significantly enhanced cell proliferation and vascularization, while the hydrogel and Cu ²⁺ exhibited potent antibacterial activity.
• The multifunctional platform accelerated wound healing in diabetic models, showing improved flap graft survival potential.

Conclusions:

• The developed HemV@dMPN/HPC hydrogel is a promising multifunctional therapeutic strategy for large diabetic skin defects.
• This platform effectively addresses key challenges in diabetic wound healing, including impaired vascularization, infection, and inflammation.
• The HemV@dMPN/HPC system holds potential for improving flap graft survival and overall treatment outcomes in diabetic patients.